Lifeward soars on FDA nod for exoskeleton device

Lifeward

13/03/2025 14:32

** U.S.-listed shares of Israel-based medical device maker Lifeward 2RW.MU, LFWD.O rise 79% to $2.63

** Stock set for biggest percentage gain in over three years

** Co says U.S. FDA has approved ReWalk 7, a new exoskeleton device that helps people with spinal cord injuries stand and walk

** Exoskeleton device is a wearable robotic system that helps people move by providing support and enhancing their physical abilities

** In June 2014, ReWalk received its first approval from FDA in the U.S. for use at home and in the community with a companion

** ReWalk 7 to be sold in the U.S. soon, co says

** Stock fell 72.2% in 2024

 (Reporting by Kamal Choudhury in Bengaluru)

 ((Kamal.Choudhury@thomsonreuters.com;))